Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; clinical trial reforms; FDA policy issues
Source: Senate LDA
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; clinical trial reforms; FDA policy issues
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · first_quarter · Q1
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · Q2
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · second_quarter · Q2
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · first_quarter · Q1
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · 2A
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · fourth_quarter · Q4
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · second_quarter · Q2
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act); American Rescue Plan Act, 2021 (HR.1319)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"; American Rescue Plan Act, 2021 (HR.1319)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · first_quarter · 1A
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"; American Rescue Plan Act, 2021 (HR.1319)
Administration Immigration Proclamation on non-immigrant visa categories
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act); American Rescue Plan Act, 2021 (HR.1319)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · first_quarter · Q1
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"; Consolifdated Act 2021 (HR 13)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; Prescription Drug Pricing Reduction Act (PDPRA - S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act - S.1712); Consolidated Appropriations Act, 2021 (HR.133)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · fourth_quarter · Q4
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage, and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S.1712); Consolidated Appropriations Act, 2021 (H.R.133)
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · third_quarter · Q3
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage, and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S. 1712)
Administration Immigration Proclamation on non-immigrant visa categories
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)(S.4199); Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2019 (DISARM Act)(S. 1712)
Issues related to intellectual property protection and market access within current trade negotiations; Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, US-UK, US-Kenya, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2020 · first_quarter · Q1
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Patient protection; drug supply chain and shortages; Drug pricing and value; Lower Health Care Costs Act (S 1895); Transparency; Intellectual Property
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · fourth_quarter · Q4
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value; Prescription Drug Pricing Reduction Act (PDPRA)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · third_quarter · Q3
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Patient protection; Drug shortages; Drug pricing and value; Lower Health Care Costs Act (S 1895); Transparency; Intellectual Property
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · 2A
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2019 · second_quarter · Q2
Intellectual property; Dormant Therapies Act; 340B Program; PPACA
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Administration Immigration Proclamation on non-immigrant visa categories
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Administration Immigration Proclamation on non-immigrant visa categories
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Administration Immigration Proclamation on non-immigrant visa categories
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Administration Immigration Proclamation on non-immigrant visa categories
Patient protection; drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual Property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"; Consolidated Appropriations Act, 2021 (H.R.133)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual Property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Administration Immigration Proclamation on non-immigrant visa categories
Patient protection; drug supply chain and shortages; Drug pricing and value; Transparency; Intellectual Property; Antimicrobial resistance; Health insurance accessibility
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Anti-counterfeiting; Patient safety; Drug pedigree; Serialization and traceability issues; Drug Quality and Security Act; Protecting consumers from illegal online drug sales; Promoting public-private partnerships; UN High Level Panel on Access to Medicines (NHHLP) and other multi-lateral threats to IP and the biopharmaceutical industry; Drug importation
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug shortages; Drug pricing and value; Lower Health Care Costs Act (S 1895); Transparency; Intellectual Property
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value; Senate Finance bill; Prescription Drug Pricing Reduction Act
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug shortages; Drug pricing and value; Dormant Therapies Act; PDUFA; BSUFA; Lower Health Care Costs Act (S 1895)
Intellectual property; Dormant Therapies Act; 340B Program; PPACA; Medicare & Meidcaid prescription drug reimbursement and value
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market acccess within current trade negotiations; Turkey IPR and Pricing; Canada IP; USMCA Passage; Saudi Arabia; Thailand OCPA; Malaysia Compulsory Licenses; Special 301; Trade talks - US-Japan, US-China, US-EU, and US-UK
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)